2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery: The task force on patient blood management for adult cardiac surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA)

European Journal of Cardio-thoracic Surgery

Volumn 53, Issue 1, 2018, Pages 79-111

  Pagano, Domenico ^a   Milojevic, Milan ^b   Meesters, Michael I ^b   Benedetto, Umberto ^a   Bolliger, Daniel ^b   Heymann, Christian von ^b   Jeppsson, Anders ^b   Koster, Andreas ^b   Osnabrugge, Ruben L ^b   Ranucci, Marco ^b   Ravn, Hanne Berg ^b   Vonk, Alexander B A ^b   Wahba, Alexander ^b   Boer, Christa ^b   von Ballmoos, Moritz W V Wyler ^b   Petricevic, Mate ^b   Kappetein, Arie Pieter ^b   Sousa Uva, Miguel ^b   Trummer, Georg ^b   Rosseel, Peter M ^b   Sander, Michael ^b   Colson, Pascal ^b   Bauer, Adrian ^b   more..

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 8; DESMOPRESSIN; ERYTHROPOIETIN; FIBRINOGEN CONCENTRATE; FIBRINOGEN RECEPTOR ANTAGONIST; FRESH FROZEN PLASMA; HEMOSTATIC AGENT; HEPARIN; IRON; LOW MOLECULAR WEIGHT HEPARIN; PROTAMINE; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOCYTE CONCENTRATE;

ANEMIA; BLOOD TRANSFUSION; CARDIOPLEGIA; CARDIOPULMONARY BYPASS; COLLOID; CRYSTALLOID; DUAL ANTIPLATELET THERAPY; ERYTHROCYTE CONCENTRATE; EXTRACORPOREAL CIRCULATION; HEALTH CARE ORGANIZATION; HEART HEMODYNAMICS; HEART SURGERY; HEMODILUTION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTRAOPERATIVE PERIOD; IRON THERAPY; MATERIAL COATING; MINIMALLY INVASIVE CARDIAC SURGERY; OFF PUMP SURGERY; OPERATIVE BLOOD LOSS; POINT OF CARE TESTING; PRACTICE GUIDELINE; PREOPERATIVE CARE; PREOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SURGICAL TECHNIQUE; ULTRAFILTRATION; ADULT; CARDIOLOGY; EUROPE; MEDICAL SOCIETY; POSTOPERATIVE HEMORRHAGE; PROCEDURES;

ADULT; BLOOD TRANSFUSION; CARDIAC SURGICAL PROCEDURES; CARDIOLOGY; EUROPE; HUMANS; POSTOPERATIVE HEMORRHAGE; PRACTICE GUIDELINES AS TOPIC; SOCIETIES, MEDICAL;

EID: 85045060971     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezx325     Document Type: Review

References (305)

1. Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, McCluskey SA et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004;44:1453-62
2. Ranucci M, Bozzetti G, Ditta A, Cotza M, Carboni G, Ballotta A. Surgical reexploration after cardiac operations: why a worse outcome? Ann Thorac Surg 2008;86:1557-62
3. Paone G, Likosky DS, Brewer R, Theurer PF, Bell GF, Cogan CM et al. Transfusion of 1 and 2 units of red blood cells is associated with increased morbidity and mortality. Ann Thorac Surg 2014;97:87-93; discussion 93-4
4. Frojd V, Jeppsson A. Reexploration for bleeding and its association with mortality after cardiac surgery. Ann Thorac Surg 2016;102:109-17
5. Ndrepepa G, Schuster T, Hadamitzky M, Byrne RA, Mehilli J, Neumann FJ et al. Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention. Circulation 2012;125:1424-31
6. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J et al. Standardized bleeding definitions for cardiovascular clinical trials. A Consensus Report from the Bleeding Academic Research Consortium. Circulation 2011;123:2736-47
7. Alghamdi AA, Davis A, Brister S, Corey P, Logan A. Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs. Transfusion 2006;46:1120-9
8. Ranucci M, Aronson S, Dietrich W, Dyke CM, Hofmann A, Karkouti K et al. Patient blood management during cardiac surgery: do we have enough evidence for clinical practice? J Thorac Cardiovasc Surg 2011; 142:249.e1-32
9. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP et al. 2011 update to the Society of Thoracic Surgeons and the Society of Cardiovascular Anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 2011;91:944-82
10. Goudie R, Sterne JAC, Verheyden V, Bhabra M, Ranucci M, Murphy GJ et al. Risk scores to facilitate preoperative prediction of transfusion and large volume blood transfusion associated with adult cardiac surgery. Br J Anaesth 2015;114:757-66
11. Vuylsteke A, Pagel C, Gerrard C, Reddy B, Nashef S, Aldam P et al. The Papworth Bleeding Risk Score: a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleeding. Eur J Cardiothorac Surg 2011;39:924-30
12. Karkouti K, O'Farrell R, Yau TM, Beattie WS; Reducing Bleeding in Cardiac Surgery Research Group. Prediction of massive blood transfusion in cardiac surgery. Can J Anesth 2006;53:781-94
13. Al-Khabori M, Al-Riyami AZ, Mukaddirov M, Al-Sabti H. Transfusion indication predictive score: a proposed risk stratification score for perioperative red blood cell transfusion in cardiac surgery. Vox Sang 2014; 107:269-75
14. Biancari F, Brascia D, Onorati F, Reichart D, Perrotti A, Ruggieri VG et al. Prediction of severe bleeding after coronary surgery: the WILL-BLEED Risk Score. Thromb Haemost 2017;117:445-56
15. Ranucci M, Castelvecchio S, Frigiola A, Scolletta S, Giomarelli P, Biagioli B. Predicting transfusions in cardiac surgery: the easier, the better: the Transfusion Risk and Clinical Knowledge score. Vox Sang 2009; 96:324-32
16. Kozek-Langenecker SA, Ahmed AB, Afshari A, Albaladejo P, Aldecoa C, Barauskas G et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology: first update 2016. Eur J Anaesthesiol 2017;34:332-95
17. American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management. Anesthesiology 2015;122:241-75
18. Sousa-Uva M, Head SJ, Thielmann M, Cardillo G, Benedetto U, Czerny M et al. Methodology manual for European Association for Cardio-Thoracic Surgery (EACTS) clinical guidelines. Eur J Cardiothorac Surg 2015;48:809-16
19. Cantrill JA, Sibbald B, Buetow S. The Delphi and nominal group techniques in health services research. Int J Pharm Pract 1996;4:67-74
20. Mahla E, Suarez TA, Bliden KP, Rehak P, Metzler H, Sequeira AJ et al. Platelet function measurement-based strategy to reduce bleeding and waiting time in clopidogrel-treated patients undergoing coronary artery bypass graft surgery: the timing based on platelet function strategy to reduce clopidogrel-associated bleeding related to CABG (TARGETCABG) study. Circ Cardiovasc Interv 2012;5:261-9
21. Malm CJ, Hansson EC, Akesson J, Andersson M, Hesse C, Shams Hakimi C et al. Preoperative platelet function predicts perioperative bleeding complications in ticagrelor-treated cardiac surgery patients: a prospective observational study. Br J Anaesth 2016;117:309-15
22. Mahla E, Prueller F, Farzi S, Pregartner G, Raggam RB, Beran E et al. Does platelet reactivity predict bleeding in patients needing urgent coronary artery bypass grafting during dual antiplatelet therapy? Ann Thorac Surg 2016;102:2010-7
23. Blome M, Isgro F, Kiessling AH, Skuras J, Haubelt H, Hellstern P et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005;93:1101-7
24. Bosch Y, Al Dieri R, ten Cate H, Nelemans P, Bloemen S, Hemker C et al. Preoperative thrombin generation is predictive for the risk of blood loss after cardiac surgery: a research article. J Cardiothorac Surg 2013;8:154
25. Karlsson M, Ternstrom L, Hyllner M, Baghaei F, Nilsson S, Jeppsson A. Plasma fibrinogen level, bleeding, and transfusion after on-pump coronary artery bypass grafting surgery: a prospective observational study. Transfusion 2008;48:2152-8
26. Ranucci M, Jeppsson A, Baryshnikova E. Pre-operative fibrinogen supplementation in cardiac surgery patients: an evaluation of different trigger values. Acta Anaesthesiol Scand 2015;59:427-33
27. Walden K, Jeppsson A, Nasic S, Backlund E, Karlsson M. Low preoperative fibrinogen plasma concentration is associated with excessive bleeding after cardiac operations. Ann Thorac Surg 2014;97:1199-206
28. Gielen C, Dekkers O, Stijnen T, Schoones J, Brand A, Klautz R et al. The effects of pre-and postoperative fibrinogen levels on blood loss after cardiac surgery: a systematic review and meta-analysis. Interact CardioVasc Thorac Surg 2014;18:292-8
29. Coakley M, Hall JE, Evans C, DuffE, Billing V, Yang L et al. Assessment of thrombin generation measured before and after cardiopulmonary bypass surgery and its association with postoperative bleeding. J Thromb Haemost 2011;9:282-92
30. Reinhöfer M, Brauer M, Franke U, Barz D, Marx G, Lösche W. The value of rotation thromboelastometry to monitor disturbed perioperative haemostasis and bleeding risk in patients with cardiopulmonary bypass. Blood Coagul Fibrinolysis 2008;19:212-9
31. Petricevic M, Biocina B, Milicic D, Konosic S, Svetina L, Lekic A et al. Bleeding risk assessment using whole blood impedance aggregometry and rotational thromboelastometry in patients following cardiac surgery. J Thromb Thrombolysis 2013;36:514-26
32. Ranucci M, Baryshnikova E, Soro G, Ballotta A, De Benedetti D, Conti D. Multiple electrode whole-blood aggregometry and bleeding in cardiac surgery patients receiving thienopyridines. Ann Thorac Surg 2011; 91:123-9
33. Ranucci M, Colella D, Baryshnikova E, Di Dedda U, Hemmings HC; Surgical, Clinical Outcome Research Group. Effect of preoperative P2Y12 and thrombin platelet receptor inhibition on bleeding after cardiac surgery. Br J Anaesth 2014;113:970-6
34. Mangano DT; Multicenter Study of Perioperative Ischemia Research Group. Aspirin and mortality from coronary bypass surgery. N Engl J Med 2002;347:1309-17
35. Musleh G, Dunning J. Does aspirin 6 h after coronary artery bypass grafting optimise graft patency? Interact CardioVasc Thorac Surg 2003; 2:413-5
36. Smith PK, Goodnough LT, Levy JH, Poston RS, Short MA, Weerakkody GJ et al. Mortality benefit with prasugrel in the TRITON-TIMI 38 coronary artery bypass grafting cohort: risk-adjusted retrospective data analysis. J Am Coll Cardiol 2012;60:388-96
37. Hansson EC, Jideus L, Aberg B, Bjursten H, Dreifaldt M, Holmgren A et al. Coronary artery bypass grafting-related bleeding complications in patients treated with ticagrelor or clopidogrel: a nationwide study. Eur Heart J 2016;37:189-97
38. Gherli R, Mariscalco G, Dalen M, Onorati F, Perrotti A, Chocron S et al. Safety of preoperative use of ticagrelor with or without aspirin compared with aspirin alone in patients with acute coronary syndromes undergoing coronary artery bypass grafting. JAMA Cardiol 2016; 1:921-8
39. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015;373:823-33
40. O'Donnell MJ, Kearon C, Johnson J, Robinson M, Zondag M, Turpie I et al. Brief communication: preoperative anticoagulant activity after bridging low-molecular-weight heparin for temporary interruption of warfarin. Ann Intern Med 2007;146:184-7
41. Medalion B, Frenkel G, Patachenko P, Hauptman E, Sasson L, Schachner A. Preoperative use of enoxaparin is not a risk factor for postoperative bleeding after coronary artery bypass surgery. J Thorac Cardiovasc Surg 2003;126:1875-9
42. Landenhed M, Johansson M, Erlinge D, Olsson ML, Bjursten H. Fondaparinux or enoxaparin: a comparative study of postoperative bleeding in coronary artery bypass grafting surgery. Scand Cardiovasc J 2010;44:100-6
43. Spyropoulos AC, Turpie AG, Dunn AS, Spandorfer J, Douketis J, Jacobson A et al. Clinical outcomes with unfractionated heparin or lowmolecular-weight heparin as bridging therapy in patients on long-term oral anticoagulants: the REGIMEN registry. J Thromb Haemost 2006; 4:1246-52
44. Jones HU, Muhlestein JB, Jones KW, Bair TL, Lavasani F, Sohrevardi M et al. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports. Circulation 2002; 106(12 Suppl 1):I19-22
45. Spyropoulos AC, Turpie AG, Dunn AS, Kaatz S, Douketis J, Jacobson A et al. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardiol 2008;102:883-9
46. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Intern Med 2004;164:1319-26
47. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324:71-86
48. Hastings S, Myles P, McIlroy D. Aspirin and coronary artery surgery: a systematic review and meta-analysis. Br J Anaesth 2015;115:376-85
49. Sun JC, Whitlock R, Cheng J, Eikelboom JW, Thabane L, Crowther MA et al. The effect of pre-operative aspirin on bleeding, transfusion, myocardial infarction, and mortality in coronary artery bypass surgery: a systematic review of randomized and observational studies. Eur Heart J 2008;29:1057-71
50. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T et al. Stopping vs. continuing aspirin before coronary artery surgery. N Engl J Med 2016;374:728-37
51. Deja MA, Kargul T, Domaradzki W, Stačel T, Mazur W, Wojakowski W. Effects of preoperative aspirin in coronary artery bypass grafting: a double-blind, placebo-controlled, randomized trial. J Thorac Cardiovasc Surg 2012;144:204-9
52. Morawski W, Sanak M, Cisowski M, Szczeklik M, Szczeklik W, Dropinski J et al. Prediction of the excessive perioperative bleeding in patients undergoing coronary artery bypass grafting: role of aspirin and platelet glycoprotein IIIa polymorphism. J Thorac Cardiovasc Surg 2005;130:791-6
53. Hansson EC, Shams Hakimi C, Astrom-Olsson K, Hesse C, Wallen H, Dellborg M et al. Effects of ex vivo platelet supplementation on platelet aggregability in blood samples from patients treated with acetylsalicylic acid, clopidogrel, or ticagrelor. Br J Anaesth 2014;112:570-5
54. Martin AC, Berndt C, Calmette L, Philip I, Decouture B, Gaussem P et al. The effectiveness of platelet supplementation for the reversal of ticagrelor-induced inhibition of platelet aggregation: an in-vitro study. Eur J Anaesthesiol 2016;33:361-7
55. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502
56. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
57. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15
58. Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J 2011;32:2933-44
59. Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68:1082-115
60. Qamar A, Bhatt DL. Current status of data on cangrelor. Pharmacol Ther 2016;159:102-9
61. Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ et al. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Circulation 2004;110:1202-8
62. Held C, Asenblad N, Bassand JP, Becker RC, Cannon CP, Claeys MJ et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol 2011; 57:672-84
63. Tomsic A, Schotborgh MA, Manshanden JS, Li WW, de Mol BA. Coronary artery bypass grafting-related bleeding complications in patients treated with dual antiplatelet treatment. Eur J Cardiothorac Surg 2016;50:849-56
64. Pickard AS, Becker RC, Schumock GT, Frye CB. Clopidogrel-associated bleeding and related complications in patients undergoing coronary artery bypass grafting. Pharmacotherapy 2008;28:376-92
65. Purkayastha S, Athanasiou T, Malinovski V, Tekkis P, Foale R, Casula R et al. Does clopidogrel affect outcome after coronary artery bypass grafting? A meta-analysis. Heart 2006;92:531-2
66. Kolh P, Windecker S, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2014;46:517-92
67. Ferraris VA, Saha SP, Oestreich JH, Song HK, Rosengart T, Reece TB et al. 2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. Ann Thorac Surg 2012;94:1761-81
68. Wallentin L. P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use. Eur Heart J 2009;30:1964-77
69. Gurbel PA, Bliden KP, Butler K, Tantry US, GesheffT, Wei C et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009; 120:2577-85
70. Storey RF, Bliden KP, Ecob R, Karunakaran A, Butler K, Wei C et al. Earlier recovery of platelet function after discontinuation of treatment with ticagrelor compared with clopidogrel in patients with high antiplatelet responses. J Thromb Haemost. 2011;9:1730-7
71. Kwak YL, Kim JC, Choi YS, Yoo KJ, Song Y, Shim JK. Clopidogrel responsiveness regardless of the discontinuation date predicts increased blood loss and transfusion requirement after offpump coronary artery bypass graft surgery. J Am Coll Cardiol 2010; 56:1994-2002
72. Savonitto S, D'Urbano M, Caracciolo M, Barlocco F, Mariani G, Nichelatti M et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of 0bridging0 antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 2010;104:285-91
73. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:234S-64S
74. Dyke CM, Jennings LK, Maier G, Andreou C, Daly R, Tamberella MR. Preoperative platelet inhibition with eptifibatide during coronary artery bypass grafting with cardiopulmonary bypass. J Cardiovasc Pharmacol Ther 2007;12:54-60
75. De Carlo M, Maselli D, Cortese B, Ciabatti N, Gistri R, Levantino M et al. Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors. Int J Cardiol 2008;123:229-33
76. Boeken U, Litmathe J, Kurt M, Feindt P, Gams E. CABG-procedures in patients with pretreatment with the GPIIb/IIIa-receptor antagonist tirofiban (Aggrastat): modification of perioperative management? Int J Cardiol 2008;127:257-9
77. Kincaid EH, Monroe ML, Saliba DL, Kon ND, Byerly WG, Reichert MG. Effects of preoperative enoxaparin versus unfractionated heparin on bleeding indices in patients undergoing coronary artery bypass grafting. Ann Thorac Surg 2003;76:124-8; discussion 8
78. Ashikhmina E, Tomasello N, Connors JM, Jahanyar J, Davidson M, Mizuguchi KA. Type A aortic dissection in a patient on dabigatran: hemostasis post circulatory arrest. Ann Thorac Surg 2014;98:2215-6
79. Stein P, Bosshart M, Brand B, Schlicker A, Spahn DR, Bettex D. Dabigatran anticoagulation and Stanford type A aortic dissection: lethal coincidence: case report with literature review. Acta Anaesthesiol Scand 2014;58:630-7
80. Crapelli GB, Bianchi P, Isgro G, Biondi A, de Vincentiis C, Ranucci M. A case of fatal bleeding following emergency surgery on an ascending aorta intramural hematoma in a patient taking dabigatran. J Cardiothorac Vasc Anesth 2016;30:1027-31
81. Weltert L, Rondinelli B, Bello R, Falco M, Bellisario A, Maselli D et al. A single dose of erythropoietin reduces perioperative transfusions in cardiac surgery: results of a prospective single-blind randomized controlled trial. Transfusion 2015;55:1644-54
82. Weltert L, D'Alessandro S, Nardella S, Girola F, Bellisario A, Maselli D et al. Preoperative very short-term, high-dose erythropoietin administration diminishes blood transfusion rate in off-pump coronary artery bypass: a randomized blind controlled study. J Thorac Cardiovasc Surg 2010;139:621-6; discussion 6-7
83. Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology 2011;115:929-37
84. Hogan M, Klein AA, Richards T. The impact of anaemia and intravenous iron replacement therapy on outcomes in cardiac surgery. Eur J Cardiothorac Surg 2015;47:218-26
85. Matsuda S, Fukui T, Shimizu J, Takao A, Takanashi S, Tomoike H. Associations between preoperative anemia and outcomes after offpump coronary artery bypass grafting. Ann Thorac Surg 2013; 95:854-60
86. Zhang L, Hiebert B, Zarychanski R, Arora RC; Cardiovascular Health Research in Manitoba Investigator Group. Preoperative anemia does not increase the risks of early surgical revascularization after myocardial infarction. Ann Thorac Surg 2013;95:542-7
87. Cutrell JB, Barros N, McBroom M, Luby J, Minhajuddin A, Ring WS et al. Risk factors for deep sternal wound infection after cardiac surgery: influence of red blood cell transfusions and chronic infection. Am J Infect Control 2016;44:1302-9
88. Engoren M, Schwann TA, Habib RH, Neill SN, Vance JL, Likosky DS. The independent effects of anemia and transfusion on mortality after coronary artery bypass. Ann Thorac Surg 2014;97:514-20
89. von Heymann C, Kaufner L, Sander M, Spies C, Schmidt K, Gombotz H et al. Does the severity of preoperative anemia or blood transfusion have a stronger impact on long-term survival after cardiac surgery? J Thorac Cardiovasc Surg 2016;152:1412-20
90. Garrido-Martin P, Nassar-Mansur MI, de la Llana-Ducros R, Virgos-Aller TM, Rodriguez Fortunez PM, Avalos-Pinto R et al. The effect of intravenous and oral iron administration on perioperative anaemia and transfusion requirements in patients undergoing elective cardiac surgery: a randomized clinical trial. Interact CardioVasc Thorac Surg 2012; 15:1013-8
91. Johansson PI, Rasmussen AS, Thomsen LL. Intravenous iron isomaltoside 1000 (Monofer(R)) reduces postoperative anaemia in preoperatively non-anaemic patients undergoing elective or subacute coronary artery bypass graft, valve replacement or a combination thereof: a randomized double-blind placebo-controlled clinical trial (the PROTECT trial). Vox Sang 2015;109:257-66
92. Kulier A, Levin J, Moser R, Rumpold-Seitlinger G, Tudor IC, Snyder-Ramos SA et al. Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 2007; 116:471-9
93. Karkouti K, Wijeysundera DN, Beattie WS; Reducing Bleeding in Cardiac Surgery Investigators. Risk associated with preoperative anemia in cardiac surgery: a multicenter cohort study. Circulation 2008;117:478-84
94. Kozek-Langenecker SA, Afshari A, Albaladejo P, Santullano CA, De Robertis E, Filipescu DC et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. Eur J Anaesthesiol 2013;30:270-382
95. Menkis AH, Martin J, Cheng DC, Fitzgerald DC, Freedman JJ, Gao C et al. Drug, devices, technologies, and techniques for blood management in minimally invasive and conventional cardiothoracic surgery: a consensus statement from the International Society for Minimally Invasive Cardiothoracic Surgery (ISMICS) 2011. Innovations (Phila) 2012;7:229-41
96. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Chan CT, Wong PY et al. Advance targeted transfusion in anemic cardiac surgical patients for kidney protection: an unblinded randomized pilot clinical trial. Anesthesiology 2012;116:613-21
97. Deppe AC, Arbash W, Kuhn EW, Slottosch I, Scherner M, Liakopoulos OJ et al. Current evidence of coronary artery bypass grafting off-pump versus on-pump: a systematic review with meta-analysis of over 16, 900 patients investigated in randomized controlled trialsdagger. Eur J Cardiothorac Surg 2016;49:1031-41; discussion 41
98. Puskas JD, Martin J, Cheng DC, Benussi S, Bonatti JO, Diegeler A et al. ISMICS consensus conference and statements of randomized controlled trials of off-pump versus conventional coronary artery bypass surgery. Innovations (Phila) 2015;10:219-29
99. Anastasiadis K, Antonitsis P, Haidich AB, Argiriadou H, Deliopoulos A, Papakonstantinou C. Use of minimal extracorporeal circulation improves outcome after heart surgery; a systematic review and meta-analysis of randomized controlled trials. Int J Cardiol 2013;164: 158-69
100. Harling L, Warren OJ, Martin A, Kemp PR, Evans PC, Darzi A et al. Do miniaturized extracorporeal circuits confer significant clinical benefit without compromising safety? A meta-analysis of randomized controlled trials. ASAIO J 2011;57:141-51
101. Sundermann SH, Sromicki J, Rodriguez Cetina Biefer H, Seifert B, Holubec T, Falk V et al. Mitral valve surgery: right lateral minithoracotomy or sternotomy? A systematic review and meta-analysis. J Thorac Cardiovasc Surg 2014;148:1989-95.e4
102. Falk V, Cheng DC, Martin J, Diegeler A, Folliguet TA, Nifong LW et al. Minimally invasive versus open mitral valve surgery: a consensus statement of the international society of minimally invasive coronary surgery (ISMICS) 2010. Innovations (Phila) 2011;6:66-76
103. Phan K, Xie A, Di Eusanio M, Yan TD. A meta-analysis of minimally invasive versus conventional sternotomy for aortic valve replacement. Ann Thorac Surg 2014;98:1499-511
104. Tavilla G, Bruggemans EF, Gielen CL, Brand A, van den Hout WB, Klautz RJ et al. Multicentre randomized clinical trial to investigate the costeffectiveness of an allogeneic single-donor fibrin sealant after coronary artery bypass grafting (FIBER Study). Br J Surg 2015;102:1338-47
105. Lamy A, Devereaux PJ, Prabhakaran D, Taggart DP, Hu S, Paolasso E et al. Off-pump or on-pump coronary-artery bypass grafting at 30 days. N Engl J Med 2012;366:1489-97
106. Diegeler A, Borgermann J, Kappert U, Breuer M, Boning A, Ursulescu A et al. Off-pump versus on-pump coronary-artery bypass grafting in elderly patients. N Engl J Med 2013;368:1189-98
107. Anastasiadis K, Murkin J, Antonitsis P, Bauer A, Ranucci M, Gygax E et al. Use of minimal invasive extracorporeal circulation in cardiac surgery: principles, definitions and potential benefits. A position paper from the Minimal invasive Extra-Corporeal Technologies international Society (MiECTiS). Interact CardioVasc Thorac Surg 2016;22:647-62
108. Carless PA, Henry DA, Anthony DM. Fibrin sealant use for minimising peri-operative allogeneic blood transfusion. Cochrane Database Syst Rev 2003;2:CD004171
109. Abrishami A, Chung F, Wong J. Topical application of antifibrinolytic drugs for on-pump cardiac surgery: a systematic review and meta-analysis. Can J Anaesth 2009;56:202-12
110. Ker K, Beecher D, Roberts I. Topical application of tranexamic acid for the reduction of bleeding. Cochrane Database Syst Rev 2013; 7:D010562
111. Gurian DB, Meneghini A, Abreu LC, Murad N, Matos LL, Pires AC et al. A randomized trial of the topical effect of antifibrinolytic epsilon aminocaproic Acid on coronary artery bypass surgery without cardiopulmonary bypass. Clin Appl Thromb Hemost 2014;20:615-20
112. Casalino S, Stelian E, Novelli E, De Jong A, Renzi L, Arellano F et al. Reduced transfusion requirements with a closed cardiopulmonary bypass system. J Cardiovasc Surg (Torino) 2008;49:363-9
113. Nakahira A, Sasaki Y, Hirai H, Matsuo M, Morisaki A, Suehiro S et al. Cardiotomy suction, but not open venous reservoirs, activates coagulofibrinolysis in coronary artery surgery. J Thorac Cardiovasc Surg 2011; 141:1289-97
114. Ranucci M, Balduini A, Ditta A, Boncilli A, Brozzi S. A systematic review of biocompatible cardiopulmonary bypass circuits and clinical outcome. Ann Thorac Surg 2009;87:1311-9
115. Landis RC, Brown JR, Fitzgerald D, Likosky DS, Shore-Lesserson L, Baker RA et al. Attenuating the systemic inflammatory response to adult cardiopulmonary bypass: a critical review of the evidence base. J Extra Corpor Technol 2014;46:197-211
116. Mahmood S, Bilal H, Zaman M, Tang A. Is a fully heparin-bonded cardiopulmonary bypass circuit superior to a standard cardiopulmonary bypass circuit? Interact CardioVasc Thorac Surg 2012;14:406-14
117. Carless PA, Henry DA, Moxey AJ, O'Connell D, Brown T, Fergusson DA. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2010;4:CD001888
118. Vermeijden WJ, Hagenaars JA, Scheeren TW, de Vries AJ. Additional postoperative cell salvage of shed mediastinal blood in cardiac surgery does not reduce allogeneic blood transfusions: a cohort study. Perfusion 2016;31:384-90
119. Vonk AB, Meesters MI, Garnier RP, Romijn JW, van Barneveld LJ, Heymans MW et al. Intraoperative cell salvage is associated with reduced postoperative blood loss and transfusion requirements in cardiac surgery: a cohort study. Transfusion 2013;53:2782-9
120. Zakkar M, Guida G, Angelini GD. Modified ultrafiltration in adult patients undergoing cardiac surgery. Interact CardioVasc Thorac Surg 2015;20:415-21
121. Boodhwani M, Williams K, Babaev A, Gill G, Saleem N, Rubens FD. Ultrafiltration reduces blood transfusions following cardiac surgery: a meta-analysis. Eur J Cardiothorac Surg 2006;30:892-7
122. Luciani GB, Menon T, Vecchi B, Auriemma S, Mazzucco A. Modified ultrafiltration reduces morbidity after adult cardiac operations: a prospective, randomized clinical trial. Circulation 2001;104:I253-9
123. Sun P, Ji B, Sun Y, Zhu X, Liu J, Long C et al. Effects of retrograde autologous priming on blood transfusion and clinical outcomes in adults: a meta-analysis. Perfusion 2013;28:238-43
124. Saczkowski R, Bernier PL, Tchervenkov CI, Arellano R. Retrograde autologous priming and allogeneic blood transfusions: a meta-analysis. Interact CardioVasc Thorac Surg 2009;8:373-6
125. Vandewiele K, Bove T, De Somer FM, Dujardin D, Vanackere M, De Smet D et al. The effect of retrograde autologous priming volume on haemodilution and transfusion requirements during cardiac surgery. Interact CardioVasc Thorac Surg 2013;16:778-83
126. Ranucci M, Baryshnikova E, Simeone F, Ranucci M, Scolletta S. Moderate-degree acidosis is an independent determinant of postoperative bleeding in cardiac surgery. Minerva Anestesiol 2015;81:885-93
127. Lee BR, Song JW, Kwak YL, Yoo KJ, Shim JK. The influence of hypothermia on transfusion requirement in patients who received clopidogrel in proximity to off-pump coronary bypass surgery. Yonsei Med J 2014; 55:224-31
128. El-Sabbagh AM, Toomasian CJ, Toomasian JM, Ulysse G, Major T, Bartlett RH. Effect of air exposure and suction on blood cell activation and hemolysis in an in vitro cardiotomy suction model. ASAIO J 2013; 59:474-9
129. Murphy GS, Hessel EA 2nd, Groom RC. Optimal perfusion during cardiopulmonary bypass: an evidence-based approach. Anesth Analg 2009; 108:1394-417
130. Lindholm L, Westerberg M, Bengtsson A, Ekroth R, Jensen E, Jeppsson A. A closed perfusion system with heparin coating and centrifugal pump improves cardiopulmonary bypass biocompatibility in elderly patients. Ann Thorac Surg 2004;78:2131-8; discussion 8
131. Mirow N, Zittermann A, Koertke H, Maleszka A, Knobl H, Coskun T et al. Heparin-coated extracorporeal circulation in combination with low dose systemic heparinization reduces early postoperative blood loss in cardiac surgery. J Cardiovasc Surg (Torino) 2008;49:277-84
132. Paparella D, Scrascia G, Rotunno C, Marraudino N, Guida P, De Palo M et al. A biocompatible cardiopulmonary bypass strategy to reduce hemostatic and inflammatory alterations: a randomized controlled trial. J Cardiothorac Vasc Anesth 2012;26:557-62
133. Lorusso R, De Cicco G, Totaro P, Gelsomino S. Effects of phosphorylcholine coating on extracorporeal circulation management and postoperative outcome: a double-blind randomized study. Interact CardioVasc Thorac Surg 2008;8:7-11
134. Marguerite S, Levy F, Quessard A, Dupeyron JP, Gros C, Steib A. Impact of a phosphorylcholine-coated cardiac bypass circuit on blood loss and platelet function: a prospective, randomized study. J Extra Corpor Technol 2012;44:5-9
135. Hosoyama K, Ito K, Kawamoto S, Kumagai K, Akiyama M, Adachi O et al. Poly-2-methoxyethylacrylate-coated cardiopulmonary bypass circuit can reduce transfusion of platelet products compared to heparincoated circuit during aortic arch surgery. J Artif Organs 2016;19:233-40
136. Thiara AS, Mollnes TE, Videm V, Andersen VY, Svennevig K, Kolset SO et al. Biocompatibility and pathways of initial complement pathway activation with Phisio-and PMEA-coated cardiopulmonary bypass circuits during open-heart surgery. Perfusion 2011;26:107-14
137. Carless PA, Henry DA, Moxey AJ, O'Connell DL, Brown T, Fergusson DA. Cell salvage for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2006;4:CD001888
138. Wang G, Bainbridge D, Martin J, Cheng D. The efficacy of an intraoperative cell saver during cardiac surgery: a meta-analysis of randomized trials. Anesth Analg 2009;109:320-30
139. Weltert L, Nardella S, Rondinelli MB, Pierelli L, De Paulis R. Reduction of allogeneic red blood cell usage during cardiac surgery by an integrated intra-and postoperative blood salvage strategy: results of a randomized comparison. Transfusion 2013;53:790-7
140. Engels GE, van Klarenbosch J, Gu YJ, van Oeveren W, de Vries AJ. Intraoperative cell salvage during cardiac surgery is associated with reduced postoperative lung injury. Interact CardioVasc Thorac Surg 2016;22:298-304
141. Gabel J, Westerberg M, Bengtsson A, Jeppsson A. Cell salvage of cardiotomy suction blood improves the balance between pro-and antiinflammatory cytokines after cardiac surgery. Eur J Cardiothorac Surg. 2013;44:506-11
142. Damgaard S, Nielsen CH, Andersen LW, Bendtzen K, Tvede M, Steinbruchel DA. Cell saver for on-pump coronary operations reduces systemic inflammatory markers: a randomized trial. Ann Thorac Surg 2010;89:1511-7
143. Jewell AE, Akowuah EF, Suvarna SK, Braidley P, Hopkinson D, Cooper G. A prospective randomised comparison of cardiotomy suction and cell saver for recycling shed blood during cardiac surgery. Eur J Cardiothorac Surg 2003;23:633-6
144. Rubens FD, Boodhwani M, Mesana T, Wozny D, Wells G, Nathan HJ. The cardiotomy trial: a randomized, double-blind study to assess the effect of processing of shed blood during cardiopulmonary bypass on transfusion and neurocognitive function. Circulation 2007;116:I89-97
145. Al-Khabori M, Al-Riyami AZ, Baskaran B, Siddiqi M, Al-Sabti H. Discriminatory power of the intraoperative cell salvage use in the prediction of platelet and plasma transfusion in patients undergoing cardiac surgery. Transfus Apher Sci 2015;53:208-12
146. Padhi S, Kemmis-Betty S, Rajesh S, Hill J, Murphy MF, Guideline Development Group. Blood transfusion: summary of NICE guidance. Br Med J 2015;351:h5832
147. Liumbruno GM, Waters JH. Unwashed shed blood: should we transfuse it? Blood Transfus 2011;9:241-5
148. Hou X, Yang F, Liu R, Yang J, Zhao Y, Wan C et al. Retrograde autologous priming of the cardiopulmonary bypass circuit reduces blood transfusion in small adults: a prospective, randomized trial. Eur J Anaesthesiol 2009;26:1061-6
149. Nathan HJ, Parlea L, Dupuis JY, Hendry P, Williams KA, Rubens FD et al. Safety of deliberate intraoperative and postoperative hypothermia for patients undergoing coronary artery surgery: a randomized trial. J Thorac Cardiovasc Surg 2004;127:1270-5
150. Vonk AB, Veerhoek D, van den Brom CE, van Barneveld LJ, Boer C. Individualized heparin and protamine management improves rotational thromboelastometric parameters and postoperative hemostasis in valve surgery. J Cardiothorac Vasc Anesth 2014;28:235-41
151. Noui N, Zogheib E, Walczak K, Werbrouck A, Amar AB, Dupont H et al. Anticoagulation monitoring during extracorporeal circulation with the Hepcon/HMS device. Perfusion 2012;27:214-20
152. Hoenicka M, Rupp P, Muller-Eising K, Deininger S, Kunert A, Liebold A et al. Anticoagulation management during multivessel coronary artery bypass grafting: a randomized trial comparing individualized heparin management and conventional hemostasis management. J Thromb Haemost 2015;13:1196-206
153. Wang J, Ma HP, Zheng H. Blood loss after cardiopulmonary bypass, standard vs titrated protamine: a meta-analysis. Neth J Med 2013; 71:123-7
154. Meesters MI, Veerhoek D, de Lange F, de Vries JW, de Jong JR, Romijn JW et al. Effect of high or low protamine dosing on postoperative bleeding following heparin anticoagulation in cardiac surgery. A randomised clinical trial. Thromb Haemost 2016;116:251-61
155. Avidan MS, Levy JH, Scholz J, Delphin E, Rosseel PM, Howie MB et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. Anesthesiology 2005;102:276-84
156. Avidan MS, Levy JH, van Aken H, Feneck RO, Latimer RD, Ott E et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. J Thorac Cardiovasc Surg 2005; 130:107-13
157. Finley A, Greenberg C. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass. Anesth Analg 2013; 116:1210-22
158. Hofmann B, Bushnaq H, Kraus FB, Raspe C, Simm A, Silber RE et al. Immediate effects of individualized heparin and protamine management on hemostatic activation and platelet function in adult patients undergoing cardiac surgery with tranexamic acid antifibrinolytic therapy. Perfusion 2013;28:412-8
159. Aziz KA, Masood O, Hoschtitzky JA, Ronald A. Does use of the Hepcon point-of-care coagulation monitor to optimise heparin and protamine dosage for cardiopulmonary bypass decrease bleeding and blood and blood product requirements in adult patients undergoing cardiac surgery? Interact CardioVasc Thorac Surg 2006;5:469-82
160. Pappalardo F, Franco A, Crescenzi G, De Simone F, Torracca L, Zangrillo A. Anticoagulation management in patients undergoing open heart surgery by activated clotting time and whole blood heparin concentration. Perfusion 2006;21:285-90
161. Avidan MS, Alcock EL, Da Fonseca J, Ponte J, Desai JB, Despotis GJ et al. Comparison of structured use of routine laboratory tests or near-patient assessment with clinical judgement in the management of bleeding after cardiac surgery. Br J Anaesth 2004;92:178-86
162. Slight RD, Buell R, Nzewi OC, McClelland DB, Mankad PS. A comparison of activated coagulation time-based techniques for anticoagulation during cardiac surgery with cardiopulmonary bypass. J Cardiothorac Vasc Anesth 2008;22:47-52
163. Radulovic V, Laffin A, Hansson KM, Backlund E, Baghaei F, Jeppsson A. Heparin and protamine titration does not improve haemostasis after cardiac surgery: a prospective randomized study. PLoS One 2015; 10:e0130271
164. Teoh KH, Young E, Blackall MH, Roberts RS, Hirsh J. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg 2004;128:211-9
165. Koster A, Borgermann J, Gummert J, RudloffM, Zittermann A, Schirmer U. Protamine overdose and its impact on coagulation, bleeding, and transfusions after cardiopulmonary bypass: results of a randomized double-blind controlled pilot study. Clin Appl Thromb Hemost 2014; 20:290-5
166. Slaughter TF, Mark JB, El-Moalem H, Hayward KA, Hilton AK, Hodgins LP et al. Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation. Blood Coagul Fibrinolysis 2001;12:25-31
167. Ranucci M, Baryshnikova E, Crapelli GB, Woodward MK, Paez A, Pelissero G. Preoperative antithrombin supplementation in cardiac surgery: a randomized controlled trial. J Thorac Cardiovasc Surg 2013; 145:1393-9
168. Linkins LA, Dans AL, Moores LK, Bona R, Davidson BL, Schulman S et al. Treatment and prevention of heparin-induced thrombocytopenia: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141:e495S-530S
169. Warkentin TE, Sheppard JA. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin. Blood 2014;123:2485-93
170. Lo GK, Sigouin CS, Warkentin TE. What is the potential for overdiagnosis of heparin-induced thrombocytopenia? Am J Hematol 2007;82: 1037-43
171. Smedira NG, Dyke CM, Koster A, Jurmann M, Bhatia DS, Hu T et al. Anticoagulation with bivalirudin for off-pump coronary artery bypass grafting: the results of the EVOLUTION-OFF study. J Thorac Cardiovasc Surg 2006;131:686-92
172. Dyke CM, Aldea G, Koster A, Smedira N, Avery E, Aronson S et al. Offpump coronary artery bypass with bivalirudin for patients with heparininduced thrombocytopenia or antiplatelet factor four/heparin antibodies. Ann Thorac Surg 2007;84:836-9
173. Dyke CM, Smedira NG, Koster A, Aronson S, McCarthy HL 2nd, Kirshner R et al. A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. J Thorac Cardiovasc Surg 2006;131:533-9
174. Koster A, Dyke CM, Aldea G, Smedira NG, McCarthy HL 2nd, Aronson S et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial. Ann Thorac Surg 2007;83:572-7
175. Warkentin TE, Greinacher A, Koster A. Bivalirudin. Thromb Haemost 2008;99:830-9
176. Palatianos G, Michalis A, Alivizatos P, Lacoumenda S, Geroulanos S, Karabinis A et al. Perioperative use of iloprost in cardiac surgery patients diagnosed with heparin-induced thrombocytopenia-reactive antibodies or with true HIT (HIT-reactive antibodies plus thrombocytopenia): an 11-year experience. Am J Hematol 2015;90:608-17
177. Koster A, Meyer O, Fischer T, Kukucka M, Krabatsch T, Bauer M et al. One-year experience with the platelet glycoprotein IIb/IIIa antagonist tirofiban and heparin during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II. J Thorac Cardiovasc Surg 2001;122:1254-5
178. Welsby IJ, Um J, Milano CA, Ortel TL, Arepally G. Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. Anesth Analg 2010; 110:30-5
179. Warkentin TE, Sheppard JA, Chu FV, Kapoor A, Crowther MA, Gangji A. Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. Blood 2015;125:195-8
180. Tran MH, Lin DM, Wilcox T, Schiro D, Cannesson M, Milliken J. Effects of a multimodality blood conservation schema toward improvement of intraoperative hemoglobin levels and off-pump transfusions in coronary artery bypass graft surgery. Transfusion 2014;54:2769-74
181. Vretzakis G, Kleitsaki A, Stamoulis K, Bareka M, Georgopoulou S, Karanikolas M et al. Intra-operative intravenous fluid restriction reduces perioperative red blood cell transfusion in elective cardiac surgery, especially in transfusion-prone patients: a prospective, randomized controlled trial. J Cardiothorac Surg 2010;5:7
182. Ranucci M, Conti D, Castelvecchio S, Menicanti L, Frigiola A, Ballotta A et al. Hematocrit on cardiopulmonary bypass and outcome after coronary surgery in nontransfused patients. Ann Thorac Surg 2010; 89:11-7
183. Martin K, Keller E, Gertler R, Tassani P, Wiesner G. Efficiency and safety of preoperative autologous blood donation in cardiac surgery: a matched-pair analysis in 432 patients. Eur J Cardiothorac Surg 2010; 37:1396-401
184. Dietrich W, Thuermel K, Heyde S, Busley R, Berger K. Autologous blood donation in cardiac surgery: reduction of allogeneic blood transfusion and cost-effectiveness. J Cardiothorac Vasc Anesth 2005;19:589-96
185. Carless P, Moxey A, O'Connell D, Henry D. Autologous transfusion techniques: a systematic review of their efficacy. Transfus Med 2004;14:123-44
186. Barile L, Fominskiy E, Di Tomasso N, Alpizar Castro LE, Landoni G, De Luca M et al. Acute normovolemic hemodilution reduces allogeneic red blood cell transfusion in cardiac surgery: a systematic review and metaanalysis of randomized trials. Anesth Analg 2017;124:743-52
187. Osawa EA, Rhodes A, Landoni G, Galas FR, Fukushima JT, Park CH et al. Effect of perioperative goal-directed hemodynamic resuscitation therapy on outcomes following cardiac surgery: a randomized clinical trial and systematic review. Crit Care Med 2016;44:724-33
188. Damen T, Reinsfelt B, Redfors B, Nygren A. Pressure-dependent changes in haematocrit and plasma volume during anaesthesia, a randomised clinical trial. Acta Anaesthesiol Scand 2016;60:560-8
189. Goepfert MS, Richter HP, Zu Eulenburg C, Gruetzmacher J, Rafflenbeul E, Roeher K et al. Individually optimized hemodynamic therapy reduces complications and length of stay in the intensive care unit: a prospective, randomized controlled trial. Anesthesiology 2013; 119:824-36
190. Bethlehem I, Wierda K, Visser C, Jekel L, Koopmans M, Kuiper MA. Influence of two colloidal extracorporeal primes on coagulation of cardiac surgical patients: a prospectively randomized open-label pilot trial. J Extra Corpor Technol 2014;46:293-9
191. Cho J-E, Shim J-K, Song J-W, Song J-W, Lee H-W, Kim D-H et al. Effect of 6% hydroxyethyl starch 130/0.4 as a priming solution on coagulation and inflammation following complex heart surgery. Yonsei Med J 2014; 55:625-34
192. Kuitunen AH, Hynynen MJ, Vahtera E, Salmenpera MT. Hydroxyethyl starch as a priming solution for cardiopulmonary bypass impairs hemostasis after cardiac surgery. Anesth Analg 2004;98:291-7
193. Schramko A, Suojaranta-Ylinen R, Niemi T, Pesonen E, Kuitunen A, Raivio P et al. The use of balanced HES 130/0.42 during complex cardiac surgery; effect on blood coagulation and fluid balance: a randomized controlled trial. Perfusion 2015;30:224-32
194. Kamra C, Beney A. Human albumin in extracorporeal prime: effect on platelet function and bleeding. Perfusion 2013;28:536-40
195. Van der Linden PJ, De Hert SG, Daper A, Trenchant A, Schmartz D, Defrance P et al. 3.5% urea-linked gelatin is as effective as 6% HES 200/0.5 for volume management in cardiac surgery patients. Can J Anesth 2004;51:236-41
196. Kasper SM, Meinert P, Kampe S, Gorg C, Geisen C, Mehlhorn U et al. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology 2003;99:42-7
197. Gurbuz HA, Durukan AB, Salman N, Tavlasoglu M, Durukan E, Ucar HI et al. Hydroxyethyl starch 6%, 130/0.4 vs. a balanced crystalloid solution in cardiopulmonary bypass priming: a randomized, prospective study. J Cardiothorac Surg 2013;8:71
198. Min JOS, Ramzisham ARM, Zamrin MD. Is 6% hydroxyethyl starch 130/0.4 safe in coronary artery bypass graft surgery? Asian Cardiovasc Thorac Ann 2009;17:368-72
199. Vanhoonacker J, Ongenae M, Vanoverschelde H, Donadoni R. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for cardiopulmonary bypass priming: the effects on postoperative bleeding and volume expansion needs after elective CABG. Acta Anaesthesiol Belg 2009; 60:91-7
200. Hecht-Dolnik M, Barkan H, Taharka A, Loftus J. Hetastarch increases the risk of bleeding complications in patients after off-pump coronary bypass surgery: a randomized clinical trial. J Thorac Cardiovasc Surg 2009; 138:703-11
201. Van der Linden PJ, De Hert SG, Deraedt D, Cromheecke S, De Decker K, De Paep R et al. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesth Analg 2005;101:629-34
202. Skhirtladze K, Base EM, Lassnigg A, Kaider A, Linke S, Dworschak M et al. Comparison of the effects of albumin 5%, hydroxyethyl starch 130/0.4 6%, and Ringer's lactate on blood loss and coagulation after cardiac surgery. Br J Anaesth 2014;112:255-64
203. DeFoe GR, Ross CS, Olmstead EM, Surgenor SD, Fillinger MP, Groom RC et al. Lowest hematocrit on bypass and adverse outcomes associated with coronary artery bypass grafting. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg 2001;71:769-76
204. Lewis CE, Hiratzka LF, Woods SE, Hendy MP, Engel AM. Autologous blood transfusion in elective cardiac valve operations. J Card Surg 2005; 20:513-8
205. Myles PS, Smith JA, Forbes A, Silbert B, Jayarajah M, Painter T et al. Tranexamic acid in patients undergoing coronary-artery surgery. N Engl J Med 2017;376:136-48
206. Henry DA, Carless PA, Moxey AJ, O'Connell D, Stokes BJ, Fergusson DA et al. Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2011;3:CD001886
207. Sedrakyan A, Treasure T, Elefteriades JA. Effect of aprotinin on clinical outcomes in coronary artery bypass graft surgery: a systematic review and meta-analysis of randomized clinical trials. J Thorac Cardiovasc Surg 2004;128:442-8
208. Desborough M, Sandu R, Brunskill SJ, Doree C, Trivella M, Montedori A et al. Fresh frozen plasma for cardiovascular surgery. Cochrane Database Syst Rev 2015;7:CD007614
209. Stanworth SJ, Brunskill SJ, Hyde CJ, McClelland DB, Murphy MF. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004;126:139-52
210. Casbard AC, Williamson LM, Murphy MF, Rege K, Johnson T. The role of prophylactic fresh frozen plasma in decreasing blood loss and correcting coagulopathy in cardiac surgery. A systematic review. Anaesthesia 2004;59:550-8
211. Demeyere R, Gillardin S, Arnout J, Strengers PF. Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010;99:251-60
212. Johansen M, Wikkelso A, Lunde J, Wetterslev J, Afshari A. Prothrombin complex concentrate for reversal of vitamin K antagonist treatment in bleeding and non-bleeding patients. Cochrane Database Syst Rev 2015; 7:CD010555
213. Godje O, Gallmeier U, Schelian M, Grunewald M, Mair H. Coagulation factor XIII reduces postoperative bleeding after coronary surgery with extracorporeal circulation. Thorac Cardiovasc Surg 2006;54:26-33
214. Karkouti K, von Heymann C, Jespersen CM, Korte W, Levy JH, Ranucci M et al. Efficacy and safety of recombinant factor XIII on reducing blood transfusions in cardiac surgery: a randomized, placebo-controlled, multicenter clinical trial. J Thorac Cardiovasc Surg 2013;146:927-39
215. Bilecen S, de Groot JA, Kalkman CJ, Spanjersberg AJ, Brandon Bravo Bruinsma GJ, Moons KG et al. Effect of fibrinogen concentrate on intraoperative blood loss among patients with intraoperative bleeding during high-risk cardiac surgery: a randomized clinical trial. JAMA 2017;317: 738-47
216. Wikkelso A, Lunde J, Johansen M, Stensballe J, Wetterslev J, Moller AM et al. Fibrinogen concentrate in bleeding patients. Cochrane Database Syst Rev 2013;8:CD008864
217. Fassl J, Matt P, Eckstein F, Filipovic M, Gregor M, Zenklusen U et al. Transfusion of allogeneic blood products in proximal aortic surgery with hypothermic circulatory arrest: effect of thromboelastometryguided transfusion management. J Cardiothorac Vasc Anesth 2013; 27:1181-8
218. Bilecen S, Peelen LM, Kalkman CJ, Spanjersberg AJ, Moons KG, Nierich AP. Fibrinogen concentrate therapy in complex cardiac surgery. J Cardiothorac Vasc Anesth 2013;27:12-7
219. Ortmann E, Besser MW, Sharples LD, Gerrard C, Berman M, Jenkins DP et al. An exploratory cohort study comparing prothrombin complex concentrate and fresh frozen plasma for the treatment of coagulopathy after complex cardiac surgery. Anesth Analg 2015;121:26-33
220. Bolliger D, Gorlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. Anesthesiology 2010;113:1205-19
221. Bignami E, Cattaneo M, Crescenzi G, Ranucci M, Guarracino F, Cariello C et al. Desmopressin after cardiac surgery in bleeding patients. A multicenter randomized trial. Acta Anaesthesiol Scand 2016; 60:892-900
222. Wademan BH, Galvin SD. Desmopressin for reducing postoperative blood loss and transfusion requirements following cardiac surgery in adults. Interact CardioVasc Thorac Surg 2014;18:360-70
223. Gill R, Herbertson M, Vuylsteke A, Olsen PS, von Heymann C, Mythen M et al. Safety and efficacy of recombinant activated factor VII: a randomized placebo-controlled trial in the setting of bleeding after cardiac surgery. Circulation 2009;120:21-7
224. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Syst Rev 2012; 3:CD005011
225. Adler Ma SC, Brindle W, Burton G, Gallacher S, Hong FC, Manelius I et al. Tranexamic acid is associated with less blood transfusion in offpump coronary artery bypass graft surgery: a systematic review and meta-analysis. J Cardiothorac Vasc Anesth 2011;25:26-35
226. Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. Br Med J 2012;344:e3054
227. Sharma V, Katznelson R, Jerath A, Garrido-Olivares L, Carroll J, Rao V et al. The association between tranexamic acid and convulsive seizures after cardiac surgery: a multivariate analysis in 11 529 patients. Anaesthesia 2014;69:124-30
228. Koster A, Borgermann J, Zittermann A, Lueth JU, Gillis-Januszewski T, Schirmer U. Moderate dosage of tranexamic acid during cardiac surgery with cardiopulmonary bypass and convulsive seizures: incidence and clinical outcome. Br J Anaesth 2013;110:34-40
229. Karkouti K, Beattie WS, Dattilo KM, McCluskey SA, Ghannam M, Hamdy A et al. A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery. Transfusion 2006;46:327-38
230. Mangano DT, Tudor IC, Dietzel C; Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation. The risk associated with aprotinin in cardiac surgery. N Engl J Med 2006;354:353-65
231. Walkden GJ, Verheyden V, Goudie R, Murphy GJ. Increased perioperative mortality following aprotinin withdrawal: a real-world analysis of blood management strategies in adult cardiac surgery. Intensive Care Med 2013;39:1808-17
232. Howell N, Senanayake E, Freemantle N, Pagano D. Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin. J Thorac Cardiovasc Surg 2013; 145:234-40
233. Pagano D, Howell NJ, Freemantle N, Cunningham D, Bonser RS, Graham TR et al. Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg 2008;135:495-502
234. Fergusson DA, Hebert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM et al. A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 2008;358:2319-31
235. McMullan V, Alston RP. III. Aprotinin and cardiac surgery: a sorry tale of evidence misused. Br J Anaesth 2013;110:675-8
236. Canada H. Health Canada Decision on Trasylol (Aprotinin) (21 September 2011, date last accessed)
237. Agency E. European Medicines Agency Recommends Lifting Suspension of Aprotinin; Review Finds That Benefits of All Antifibrinolytic Medicines Outweigh Risks in Restricted Range of Indications (17 February 2012, date last accessed)
238. Yang L, Stanworth S, Hopewell S, Doree C, Murphy M. Is fresh-frozen plasma clinically effective? An update of a systematic review of randomized controlled trials. Transfusion 2012;52:1673-86; quiz
239. Karkouti K, McCluskey SA, Syed S, Pazaratz C, Poonawala H, Crowther MA. The influence of perioperative coagulation status on postoperative blood loss in complex cardiac surgery: a prospective observational study. Anesth Analg 2010;110:1533-40
240. Ternstrom L, Radulovic V, Karlsson M, Baghaei F, Hyllner M, Bylock A et al. Plasma activity of individual coagulation factors, hemodilution and blood loss after cardiac surgery: a prospective observational study. Thromb Res 2010;126:e128-33
241. Theusinger OM, Baulig W, Asmis LM, Seifert B, Spahn DR. In vitro factor XIII supplementation increases clot firmness in Rotation Thromboelastometry (ROTEM). Thromb Haemost 2010;104:385-91
242. Karkouti K, Callum J, Crowther MA, McCluskey SA, Pendergrast J, Tait G et al. The relationship between fibrinogen levels after cardiopulmonary bypass and large volume red cell transfusion in cardiac surgery: an observational study. Anesth Analg 2013;117:14-22
243. Levy JH, Gill R, Nussmeier NA, Olsen PS, Andersen HF, Booth FV et al. Repletion of factor XIII following cardiopulmonary bypass using a recombinant A-subunit homodimer. A preliminary report. Thromb Haemost 2009;102:765-71
244. Hiippala ST, Myllyla GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 1995;81:360-5
245. Bolliger D, Gonsahn M, Levy JH, Williams WH, Tanaka KA. Is preoperative fibrinogen predictive for postoperative bleeding after coronary artery bypass grafting surgery? Transfusion 2009;49:2006-7; author reply 7-8
246. Tanaka KA, Esper S, Bolliger D. Perioperative factor concentrate therapy. Br J Anaesth 2013;111(Suppl 1):i35-49
247. Jeppsson A, Walden K, Roman-Emanuel C, Thimour-Bergstrom L, Karlsson M. Preoperative supplementation with fibrinogen concentrate in cardiac surgery: a randomized controlled study. Br J Anaesth 2016; 116:208-14
248. Rahe-Meyer N, Solomon C, Hanke A, Schmidt DS, Knoerzer D, Hochleitner G et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebocontrolled trial. Anesthesiology 2013;118:40-50
249. Ranucci M, Baryshnikova E, Crapelli GB, Rahe-Meyer N, Menicanti L, Frigiola A. Randomized, double-blinded, placebo-controlled trial of fibrinogen concentrate supplementation after complex cardiac surgery. J Am Heart Assoc 2015;4:e002066
250. Rahe-Meyer N, Levy JH, Mazer CD, Schramko A, Klein AA, Brat R et al. Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. Br J Anaesth 2016;117:41-51
251. Ranucci M, Baryshnikova E. Fibrinogen supplementation after cardiac surgery: insights from the Zero-Plasma trial (ZEPLAST). Br J Anaesth 2016;116:618-23
252. Fassl J, Lurati Buse G, Filipovic M, Reuthebuch O, Hampl K, Seeberger MD et al. Perioperative administration of fibrinogen does not increase adverse cardiac and thromboembolic events after cardiac surgery. Br J Anaesth 2015;114:225-34
253. Ghadimi K, Levy JH, Welsby IJ. Prothrombin complex concentrates for bleeding in the perioperative setting. Anesth Analg 2016;122: 1287-300
254. Arnekian V, Camous J, Fattal S, Rezaiguia-Delclaux S, Nottin R, Stephan F. Use of prothrombin complex concentrate for excessive bleeding after cardiac surgery. Interact CardioVasc Thorac Surg 2012;15:382-9
255. Cappabianca G, Mariscalco G, Biancari F, Maselli D, Papesso F, Cottini M et al. Safety and efficacy of prothrombin complex concentrate as first-line treatment in bleeding after cardiac surgery. Crit Care 2016; 20:5
256. Carless PA, Henry DA, Moxey AJ, O'Connell D, McClelland B, Henderson KM et al. Desmopressin for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2004;1:CD001884
257. Crescenzi G, Landoni G, Biondi-Zoccai G, Pappalardo F, Nuzzi M, Bignami E et al. Desmopressin reduces transfusion needs after surgery: a meta-analysis of randomized clinical trials. Anesthesiology 2008; 109:1063-76
258. Desborough MJ, Oakland KA, Landoni G, Crivellari M, Doree C, Estcourt LJ et al. Desmopressin for treatment of platelet dysfunction and reversal of antiplatelet agents: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost 2017;15:263-72
259. Steiner ME, Ness PM, Assmann SF, Triulzi DJ, Sloan SR, Delaney M et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med 2015;372:1419-29
260. Lacroix J, Hebert PC, Fergusson DA, Tinmouth A, Cook DJ, Marshall JC et al. Age of transfused blood in critically ill adults. N Engl J Med 2015; 372:1410-8
261. Dzieciatkowska M, Silliman CC, Moore EE, Kelher MR, Banerjee A, Land KJ et al. Proteomic analysis of the supernatant of red blood cell units: the effects of storage and leucoreduction. Vox Sang 2013;105: 210-8
262. Membe SK, Coyle D, Husereau D, Cimon K, Tinmouth A, Normandin S. Octaplas Compared with Fresh Frozen Plasma to Reduce the Risk of Transmitting Lipid-Enveloped Viruses: An Economic Analysis and Budget Impact Analysis [Internet]. 2011
263. Deppe AC, Weber C, Zimmermann J, Kuhn EW, Slottosch I, Liakopoulos OJ et al. Point-of-care thromboelastography/thromboelastometry-based coagulation management in cardiac surgery: a meta-analysis of 8332 patients. J Surg Res 2016;203:424-33
264. Serraino GF, Murphy GJ. Routine use of viscoelastic blood tests for diagnosis and treatment of coagulopathic bleeding in cardiac surgery: updated systematic review and meta-analysis. Br J Anaesth 2017; 118:823-833
265. Karkouti K, Callum J, Wijeysundera DN, Rao V, Crowther M, Grocott HP et al. Point-of-care hemostatic testing in cardiac surgery: a stepped-wedge clustered randomized controlled trial. Circulation 2016;134:1152-62
266. Murphy GJ, Pike K, Rogers CA, Wordsworth S, Stokes EA, Angelini GD et al. Liberal or restrictive transfusion after cardiac surgery. N Engl J Med 2015;372:997-1008
267. Hajjar LA, Vincent JL, Galas FR, Nakamura RE, Silva CM, Santos MH et al. Transfusion requirements after cardiac surgery: the TRACS randomized controlled trial. JAMA 2010;304:1559-67
268. von Heymann C, Sander M, Foer A, Heinemann A, Spiess B, Braun J et al. The impact of an hematocrit of 20% during normothermic cardiopulmonary bypass for elective low risk coronary artery bypass graft surgery on oxygen delivery and clinical outcome-a randomized controlled study [ISRCTN35655335]. Crit Care 2006;10:R58
269. Klausen SS, Hervig T, Seghatchian J, Reikvam H. Bacterial contamination of blood components: Norwegian strategies in identifying donors with higher risk of inducing septic transfusion reactions in recipients. Transfus Apher Sci 2014;51:97-102
270. Dwyre DM, Fernando LP, Holland PV. Hepatitis B, hepatitis C and HIV transfusion-transmitted infections in the 21st century. Vox Sang 2011; 100:92-8
271. Shaz BH, Stowell SR, Hillyer CD. Transfusion-related acute lung injury: from bedside to bench and back. Blood 2011;117:1463-71
272. Dunbar NM. Current options for transfusion-related acute lung injury risk mitigation in platelet transfusions. Curr Opin Hematol 2015;22:554-8
273. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev 2007;21:327-48
274. Blumberg N, Zhao H, Wang H, Messing S, Heal JM, Lyman GH. The intention-to-treat principle in clinical trials and meta-analyses of leukoreduced blood transfusions in surgical patients. Transfusion 2007; 47:573-81
275. Rohde JM, DimcheffDE, Blumberg N, Saint S, Langa KM, Kuhn L et al. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA 2014;311:1317-26
276. Bilgin YM, van de Watering LM, Eijsman L, Versteegh MI, Brand R, van Oers MH et al. Double-blind, randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation 2004;109:2755-60
277. Sartipy U, Holzmann MJ, Hjalgrim H, Edgren G. Red blood cell concentrate storage and survival after cardiac surgery. JAMA 2015; 314:1641-3
278. Alexander PE, Barty R, Fei Y, Vandvik PO, Pai M, Siemieniuk RA et al. Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. Blood 2016;127:400-10
279. Vamvakas EC. Relative safety of pooled whole blood-derived versus single-donor (apheresis) platelets in the United States: a systematic review of disparate risks. Transfusion 2009;49:2743-58
280. Welsby IJ, Lockhart E, Phillips-Bute B, Campbell ML, Mathew JP, Newman MF et al. Storage age of transfused platelets and outcomes after cardiac surgery. Transfusion 2010;50:2311-7
281. Ogawa S, Szlam F, Bolliger D, Nishimura T, Chen EP, Tanaka KA. The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry. Anesth Analg 2012;115:16-21
282. Wikkelso A, Wetterslev J, Moller AM, Afshari A. Thromboelastography (TEG) or thromboelastometry (ROTEM) to monitor haemostatic treatment versus usual care in adults or children with bleeding. Cochrane Database Syst Rev 2016;8:CD007871
283. Whiting P, Al M, Westwood M, Ramos IC, Ryder S, Armstrong N et al. Viscoelastic point-of-care testing to assist with the diagnosis, management and monitoring of haemostasis: a systematic review and costeffectiveness analysis. Health Technol Assess 2015;19:1-228, v-vi
284. Weber CF, Gorlinger K, Meininger D, Herrmann E, Bingold T, Moritz A et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. Anesthesiology 2012; 117:531-47
285. Song HK, von Heymann C, Jespersen CM, Karkouti K, Korte W, Levy JH et al. Safe application of a restrictive transfusion protocol in moderaterisk patients undergoing cardiac operations. Ann Thorac Surg 2014; 97:1630-5
286. Ranucci M, Aloisio T, Carboni G, Ballotta A, Pistuddi V, Menicanti L et al. Acute kidney injury and hemodilution during cardiopulmonary bypass: a changing scenario. Ann Thorac Surg 2015;100:95-100
287. Patel NN, Avlonitis VS, Jones HE, Reeves BC, Sterne JA, Murphy GJ. Indications for red blood cell transfusion in cardiac surgery: a systematic review and meta-analysis. Lancet Haematol 2015;2:e543-53
288. Nakamura RE, Vincent JL, Fukushima JT, de Almeida JP, Franco RA, Lee Park C et al. A liberal strategy of red blood cell transfusion reduces cardiogenic shock in elderly patients undergoing cardiac surgery. J Thorac Cardiovasc Surg 2015;150:1314-20
289. Kumar A, Mhaskar R, Grossman BJ, Kaufman RM, Tobian AA, Kleinman S et al. Platelet transfusion: a systematic review of the clinical evidence. Transfusion 2015;55:1116-27; quiz 5
290. Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE et al. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015;162:205-13
291. Annich GM. Extracorporeal life support: the precarious balance of hemostasis. J Thromb Haemost 2015;13(Suppl 1):S336-42
292. Bates SM, Weitz JI. Coagulation assays. Circulation 2005;112:e53-60
293. Wool GD, Lu CM; Education Committee of the Academy of Clinical Laboratory Physicians and Scientists. Pathology consultation on anticoagulation monitoring: factor X-related assays. Am J Clin Pathol 2013; 140:623-34
294. Price EA, Jin J, Nguyen HM, Krishnan G, Bowen R, Zehnder JL. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacother 2013;47:151-8
295. Adatya S, Uriel N, Yarmohammadi H, Holley CT, Feng A, Roy SS et al. Anti-factor Xa and activated partial thromboplastin time measurements for heparin monitoring in mechanical circulatory support. JACC Heart Fail 2015;3:314-22
296. Koster A, Chew D, Grundel M, Hausmann H, Grauhan O, Kuppe H et al. An assessment of different filter systems for extracorporeal elimination of bivalirudin: an in vitro study. Anesth Analg 2003;96:1316-9
297. Hoechter DJ, von Dossow V, Winter H, Muller HH, Meiser B, Neurohr C et al. The munich lung transplant group: intraoperative extracorporeal circulation in lung transplantation. Thorac Cardiovasc Surg 2015; 63:706-14
298. Bembea MM, Annich G, Rycus P, Oldenburg G, Berkowitz I, Pronovost P. Variability in anticoagulation management of patients on extracorporeal membrane oxygenation: an international survey. Pediatr Crit Care Med 2013;14:e77-84
299. Chu DC, Abu-Samra AG, Baird GL, Devers C, Sweeney J, Levy MM et al. Quantitative measurement of heparin in comparison with conventional anticoagulation monitoring and the risk of thrombotic events in adults on extracorporeal membrane oxygenation. Intensive Care Med 2015; 41:369-70
300. Yeo HJ, Kim do H, Jeon D, Kim YS, Cho WH. Low-dose heparin during extracorporeal membrane oxygenation treatment in adults. Intensive Care Med 2015;41:2020-1
301. Byrnes JW, Swearingen CJ, Prodhan P, Fiser R, Dyamenahalli U. Antithrombin III supplementation on extracorporeal membrane oxygenation: impact on heparin dose and circuit life. ASAIO J 2014;60:57-62
302. Ranucci M, Baryshnikova E, Cotza M, Carboni G, Isgro G, Carlucci C et al. Coagulation monitoring in postcardiotomy ECMO: conventional tests, point-of-care, or both? Minerva Anestesiol 2016;82:858-66
303. Ranucci M, Ballotta A, Kandil H, Isgro G, Carlucci C, Baryshnikova E et al. Bivalirudin-based versus conventional heparin anticoagulation for postcardiotomy extracorporeal membrane oxygenation. Crit Care 2011;15:R275
304. Pieri M, Agracheva N, Bonaveglio E, Greco T, De Bonis M, Covello RD et al. Bivalirudin versus heparin as an anticoagulant during extracorporeal membrane oxygenation: a case-control study. J Cardiothorac Vasc Anesth 2013;27:30-4
305. Beiderlinden M, Treschan T, Gorlinger K, Peters J. Argatroban in extracorporeal membrane oxygenation. Artif Organs 2007;31:461-5